Ashish Jain

About

I am a researcher in neuroscience with a strong background in preclinical models of autism spectrum disorder and neurodegenerative diseases. My PhD work focused on targeting the mTOR/GSK3β/CREB pathways using pharmacological modulators to improve behavioral and molecular deficits in the valproic acid model of ASD. Currently, as an ANRF-N-PDF fellow at the Centre for Brain Research, IISc Bangalore, I investigate the role of somatostatin interneurons in tauopathy using fiber photometry, viral vectors, immunohistochemistry, and transcranial electrical stimulation. My broader interests include translational therapeutics, circuit-level mechanisms of disease, and advanced neurotechnologies.

Employment

• Indian Institute of Science Bangalore Postdoctoral Associate (ANRF-N-PDF)
  2025 - Present
• Indian Institute of Science Bangalore Postdoctoral Associate
  2025 - 2025

Education

• Post Graduate Institute of Medical Education and Research Ph.D.
  2019 - 2024
• C. L. Baid Metha College Of Pharmacy M.Pharmacy
  2015 - 2017
• C.L. Baid Metha College of Pharmacy B.Pharmacy
  2011 - 2015

Projects & Funding

Projects & funding information is unavailable.

Publications (24)

• Polymorphisms in brain cholesterol homeostasis pathway as biomarkers for Alzheimer's Disease: meta-analyses of clinical evidences.
  Alzheimer’s Association International Conference (AAIC) 2025 2026
  +Save
• Pharmaco-Epigenomic response of Pimozide is mediated through miR-2909
  Integrative Biology 2026 DOI: 10.1093/intbio/zyag008
  +Save
• Valproic acid triggers a sex-independent autism-like deficits, gut-brain axis, and neurodegenerative changes in the autism model of Wistar rats
  Behavioural Pharmacology 2025 DOI: 10.1097/fbp.0000000000000839
  +Save
• Targeting the CREB pathway with Forskolin: A preclinical therapeutic approach for autism spectrum disorder.
  5th African Epilepsy Congress 2025
  +Save
• Restoring Brain Function in Autism: GSK3β Inhibition by 6-Bromoindirubin-3′-oxime Reverses Valproic Acid-induced Neuropathology
  ACS Chemical Neuroscience 2025 DOI: 10.1021/acschemneuro.5c00125
  +Save
• Adenylyl Cyclase Activator: Forskolin Mediates CREB ser133 Phosphorylation in the Hippocampus, Alleviates Autism‐Like Deficits in a Valproic Acid Model of Wistar Rats
  Journal of Neuroscience Research 2025 DOI: 10.1002/jnr.70049
  +Save
• Epl/ASD013 As a Dual-Target Therapeutic for Autism Spectrum Disorders: Modulating Glutamate Excitotoxicity and Neurobehavioral Symptoms.
  International Society for Autism Research (INSAR) 2025
  +Save
• Disrupting Maternal Behavior and Inducing Cannibalism Due to Valproic Acid: An Unexplored Insight
  Basic and Clinical Neuroscience 2024 DOI: 10.32598/bcn.2022.4410.1
  +Save
• SEW2871 reduces seizures via the sphingosine 1-phosphate receptor-1 pathway in the pentylenetetrazol and phenobarbitone kindling model of drug-refractory epilepsy
  Clinical and Experimental Pharmacology and Physiology 2024 DOI: 10.1111/1440-1681.13839
  +Save
• To evaluate the effect of endothelin receptor agonist IRL-1620 alone and in combination with donepezil in modulating neurodegeneration elicited by amyloid-β in rats
  Experimental Neurology 2024 DOI: 10.1016/j.expneurol.2024.114720
  +Save